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introduction: Fluorescence-guided surgery is one of the rapidly emerging methods of 
surgical “theranostics.” In this review, we summarize current fluorescence techniques 
used in neurosurgical practice for brain tumor patients as well as future applications of 
recent laboratory and translational studies.
Methods: Review of the literature.
Results: A wide spectrum of fluorophores that have been tested for brain surgery is 
reviewed. Beginning with a fluorescein sodium application in 1948 by Moore, fluores-
cence-guided brain tumor surgery is either routinely applied in some centers or is under 
active study in clinical trials. Besides the trinity of commonly used drugs (fluorescein 
sodium, 5-aminolevulinic acid, and indocyanine green), less studied fluorescent stains, 
such as tetracyclines, cancer-selective alkylphosphocholine analogs, cresyl violet, acri-
dine orange, and acriflavine, can be used for rapid tumor detection and pathological 
tissue examination. Other emerging agents, such as activity-based probes and targeted 
molecular probes that can provide biomolecular specificity for surgical visualization and 
treatment, are reviewed. Furthermore, we review available engineering and optical solu-
tions for fluorescent surgical visualization. Instruments for fluorescent-guided surgery are 
divided into wide-field imaging systems and hand-held probes. Recent advancements in 
quantitative fluorescence-guided surgery are discussed.
Conclusion: We are standing on the threshold of the era of marker-assisted tumor 
management. Innovations in the fields of surgical optics, computer image analysis, and 
molecular bioengineering are advancing fluorescence-guided tumor resection para-
digms, leading to cell-level approaches to visualization and resection of brain tumors.
Keywords: 5-ALA, confocal, endomicroscopy, fluorescein, fluorescence-guided surgery, fluorescent probe, 
glioma, iCG
Abbreviations: 5-ALA, 5-aminolevulenic acid; BBB, blood–brain barrier; EGFR, epidermal growth factor receptor; FITC, 
fluorescein isothiocyanate; GTR, gross total resection; ICG, indocyanine green; NIR, near-infrared; PDT, photodynamic 
therapy; PpIX, protoporphyrin IX; ROS, reactive oxygen species.
2Belykh et al. Fluorescence-Guided Precision Neuro-Oncology
Frontiers in Surgery | www.frontiersin.org October 2016 | Volume 3 | Article 55
iNTRODUCTiON
Malignant glioma is a highly invasive, heterogeneous, complex, 
and fatal tumor type, the extent of which is not precisely identifi-
able by modern imaging techniques. Despite all of the current 
treatment modalities for malignant gliomas, such as microsurgery, 
chemotherapy, and radiotherapy, there is no definitive treatment. 
Nonetheless, the maximum extent of surgical resection is associ-
ated with a longer recurrence-free period and overall survival 
of patients with glioblastomas (1, 2), low-grade gliomas (3), 
meningiomas (4), and other intracranial malignancies. Therefore, 
the initial treatment goal should be the maximal removal of the 
tumor mass. Tumor mass resection is guided intraoperatively 
by anatomically registered images (usually CT and MRI) 
incorporated into a stereotactically based image-guided surgery 
platform. Such a surgical strategy becomes a balance of aggressive 
tumor removal while producing no new or further permanent 
neurological deficit. Although there are characteristics of images 
from CT and MRI that indicate what tumor, necrosis, or edema-
tous cortex is, the main focus of surgery is achieving maximal 
resection of the invading tumor front. In light of this, researchers 
have endeavored to make any invisible part of the tumor visible 
using advanced imaging techniques.
Advances in imaging began with the philosophies of cer-
ebral localization and function, while techniques for improving 
precision and the customization of brain tumor surgery can be 
traced to the late nineteenth century. The evolution of imaging 
techniques in neurosurgery began with the first attempts at cra-
niometric localization of intracranial lesions (5). The introduc-
tion of X-rays in neurosurgery in 1896 by Krause and Cushing 
(6), pneumoencephalography in 1919 by Dandy (7, 8), and 
cerebral angiography specifically for brain tumors by Moniz in 
1927 (9, 10) were the first steps in preoperative imaging diagnosis 
of brain tumors, which was previously possible only by clinical 
neurological examination. Intraoperative stimulation in awake 
patients to increase the safety of tumor resection was performed 
by Thomas and Cushing (11). This stimulation was possible due 
to Cushing’s previous experience in mapping the motor cortex 
of primates in 1902 in the physiology laboratory of Sherrington 
(12). However, the origins of intraoperative neurophysiology 
for functional localization have roots in the works of Betz (13), 
Ferrier (14), Fritsch and Hitzig (15), and Clark and Horsley (16). 
Since the beginning of the twentieth century, several neurosur-
geons, most notably Penfield in 1928, have used intraoperative 
brain stimulation extensively to map the cortex to guide brain 
tumor resection and surgical treatment of epilepsy (17). Building 
on earlier work, intraoperative electrophysiological monitoring 
and cortical and subcortical mapping performed with the patient 
conscious remain state-of-the-art methods to elicit functions of 
brain areas and define and personalize safe boundaries of tumor 
resection (18, 19).
Techniques for visually identifying the tumor mass began in 
the mid-twentieth century. The application of the fluorescent dye 
fluorescein sodium to highlight tumor tissue during its removal 
was introduced in neurosurgery by Moore et  al. in 1948 (20), 
decades before computed tomographic (CT) scanning was intro-
duced into broad clinical practice (1973) (21–23). Fluorescein 
sodium was in use even earlier than the first operative microscopes 
used by neurosurgeons and was pioneered by Kurze in 1957 (24). 
However, fluorescent dye technology did not gain widespread 
acceptance due to the high rate of background fluorescence 
from normal brain tissue and the shortcomings of visualization 
technologies (25). Fluorescein injection for cerebrovascular and 
tumor surgery was studied in detail by Feindel in the 1960s (26). 
A major step after the introduction of CT with contrast injection 
(23) was gadolinium-enhanced MRI, introduced around 1987, 
that allowed even more precise tumor mass visualization and pre-
cise anatomical co-registration for planning surgery (27). Infrared 
frameless neuronavigation systems resulting from developments 
in stereotactic and computer technologies were rapidly adopted 
in neurosurgical operating rooms in the late 1980s (28–30). The 
virtual linkage of neuroimaging and intraoperative anatomy 
allowed a precision of nearly 2 mm, selection of the best approach 
trajectory (31), and radically improved the surgeon’s intraopera-
tive orientation. The main drawback of neuronavigation remains 
brain shift [1 cm on average (32)] as a consequence of opening 
the cranium, which significantly limits the accuracy of determin-
ing an infiltrative tumor border (33). Despite software advances 
(32), intraoperative ultrasound (34, 35), and intraoperative MRI 
corrections (36), the current (2015) technologies do not provide 
the desired accuracy for consistent, precise, and extensive resec-
tion (37). The main drawback continues to be that MR and CT 
image characteristics are not directly indicative of regional tissue 
type and cannot provide clinically applicable imaging at or near 
cellular resolution.
Accurate visualization of brain tumors marked by fluorescent 
probes and even residual tumor cells is possible with emerging 
new technologies. These emerging technologies are expected 
to become state-of-the-art tools to maximize customized brain 
tumor treatment. These technologies are the logical extension of 
the evolution of the search for precision in brain tumor surgery. 
Such technologies will allow real-time imaging interrogation of 
the brain during surgery at the cellular resolution to maximize or 
tailor brain tumor resection.
This review summarizes recent achievements and future 
perspectives of clinical, laboratory, and translational studies that 
bring fluorescence-guided neurosurgery to the cellular level, 
thereby allowing for individualized brain tumor resections, 
representing a crucial breakthrough in this field.
FLUOReSCeNT DYeS iN 
NeUROSURGeRY
In the last decade (2006–2016), the number of fluorescent 
stains and cellular tags used in preclinical studies has increased 
significantly, with many novel fluorophores awaiting approval for 
clinical use. The fluorescent probes and dyes discussed in this 
review are summarized in Table  1 (25, 38–74). Three fluores-
cent contrast agents that have been studied and used in human 
neurosurgical procedures are fluorescein sodium, indocyanine 
green (ICG), and 5-aminolevulinic acid (5-ALA), although 
not all are approved by regulatory committees in all countries. 
Other fluorophores (including acridine orange, acriflavine, cresyl 
TABLe 1 | Summary of published preclinical and early clinical data on probes and imaging equipment for potential personalized fluorescence-guided brain tumor surgery.
Name of probe Reported 
excitation 
wavelength
Reported 
reading 
emission 
wavelength
Used equipment Species tested Advantages Disadvantages Mode of 
administration 
and time 
to imaging 
(unless noted 
otherwise)
Targeted probes
IRDye 800CW-labeled 
VEGF (38) 
(Bevacizumab)
675 and 745 nm 
(in vivo)
800 nm 
(in vivo)
 1. IVIS Spectrum (PerkinElmer, Inc.)
 2. Multispectral Fluorescence Camera 
System (Institute for Biological and 
Medical Imaging, Technical University, 
Munich, Germany and SurgOptix Inc., 
Redwood Shores, CA, USA), in vivo
 3. Olympus Fluoview 300 Confocal Scan 
Box mounted on an Olympus IX 71 
inverted microscope (Olympus America 
Inc.), ex vivo
 4. Pearl Imaging System  
(LI-COR Biosciences) in vivo
Xenograft mice model 
(human ovarian, breast, 
and gastric cancers)
Distinguish submillimeter lesions 
intraoperatively. Longer lasting 
and more accurate signal for 
VEGF and EGFR2 than ICG alone. 
Bevacizumab-800CW fluorescence 
detection in extracellular matrix, 
trastuzumab-800CW fluorescence 
detection on tumor cell surface
Long half-life for 
detecting tumors. 
Long elimination time
IV, 6 days 
(optimal time)
IRDye 800CW-labeled 
human EGFR 2 
[Trastuzumab (38); 
Erbitux (39)]
675 and 745 nm 
(in vivo); 685 and 
785 nm
800 nm 
(in vivo); 720 
and 820 nm
 1. IVIS Spectrum (PerkinElmer, Inc.)
 2. Multispectral Fluorescence Camera 
System (Institute for Biological and 
Medical Imaging, Technical University 
and SurgOptix Inc.), in vivo
 3. Olympus Fluoview 300 Confocal Scan 
Box mounted on an Olympus IX 71 
inverted microscope (Olympus America 
Inc.), ex vivo
 4. Pearl Imaging System (LI-COR 
Biosciences) in vivo
Xenograft mice model 
(human ovarian, breast, 
and gastric cancers); 
Xenograft mice model 
(human breast cancer 
lymph metastasis)
Distinguish submillimeter lesions 
intraoperatively. Longer lasting 
and more accurate signal for 
VEGF and EGFR2 than ICG alone. 
Bevacizumab-800CW fluorescence 
detection in extracellular matrix, 
trastuzumab-800CW fluorescence 
detection on tumor cell surface
Long half-life for 
detecting tumors. 
Long elimination time
IV, 3–6 days 
(optimal 
time); 3 h for 
lymph node 
visualization
IRDye 800CW-labeled 
anti-EGFR nanobody 
7D12 (40, 41)
760 nm; 
656–678 nm; 
745–779 nm
774 nm; 
700 nm; 
800 nm
 1. IVIS Lumina System (PerkinElmer, Inc.) 
with ICG filter sets
 2. FLARE imaging system (Beth Israel 
Deaconess Medical Center)
 3. IVIS Spectrum (PerkinElmer, Inc.)
Xenograft mice (human 
epidermoid carcinoma); 
xenograft mice (human 
metastatic oral squamous 
cell carcinoma)
Better tumor penetration and 
distribution of nanobody probe 
in vivo (vs. cetuximab full antibody). 
Significantly higher tumor to 
background fluorescence (vs. 
cetuximab full antibody)
Not mentioned IV, 30 min 
(earliest); 2 h 
(optimal); or 24 h 
(optimal)
IRDye 680RD labeled 
EGFR inhibitor 
(cetuximab) (42)
620 nm 650–800 nm Odyssey Infrared Imaging System (LI-COR 
Biosciences, Lincoln, Nebraska), ex vivo
Xenograft mice (human 
U251 glioma)
Higher affinity for tumor than anti-
EGFR targeted affibody used in 
same study
Concentration of 
antibody in tumor 
focused primarily in 
the center
IV, 1 h
IRDye 800CW-labeled 
anti-EGFR targeted 
affibody (42)
720 nm 730–900 nm Odyssey Infrared Imaging System (LI-COR 
Biosciences), ex vivo
Xenograft mice (human 
U251 glioma)
Smaller size molecule results in 
better penetration of BBB. Higher 
concentration in outer tumor than 
antibody
30 times lower affinity 
than antibody and 
a shorter plasma 
half-life
IV, 1 h
(Continued)
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Name of probe Reported 
excitation 
wavelength
Reported 
reading 
emission 
wavelength
Used equipment Species tested Advantages Disadvantages Mode of 
administration 
and time 
to imaging 
(unless noted 
otherwise)
IRDye 800CW-labeled 
chemokine stromal 
cell derived factor-1 
(SDF-1) (43)
685 and 785 nm 702 or 
789 nm
Pearl Imaging System (LI-COR Biosciences), 
in vivo
Xenograft mice (A764 
human glioma, MCF-7 
human breast cancer)
Detected as low as 500 cells 
in vitro. Specific for tumor cells. 
Signal persisted for days
Labeled bone 
marrow, transient 
non-specific labeling 
during first 24 h was 
observed in the liver 
and skull
IV, 1-h 
visualization 
of tumors and 
background 
structures; 
24–92 h 
background 
fluorescence 
diminished, 
tumors remained 
clearly visible
IRDye 800CW-labeled 
anti-CD105 
monoclonal antibody 
(angiogenesis related) 
(44)
778 nm 806 nm Pearl Imaging System (LI-COR Biosciences) 
in vivo and in vitro
Mice with 4T1 mouse 
breast cancer; human 
MCF-7 breast cancer 
cells in cultures
Tumor could be visualized as early 
as 30 min post-injection; may be 
used in the clinic for imaging tumor 
angiogenesis
CD105 expression 
is observed only on 
actively proliferating 
tumor endothelial 
cells
IV, 30 min (early); 
16 h (optimal)
Cy5.5-labeled EGFR 
inhibitor (cetuximab) 
(45)
683 nm (max); 
630–670 nm 
(range used in 
experiment)
707 nm (max); 
685–735 nm 
(range used in 
experiment)
 1. Leica MZFL3 stereo research 
microscope (Leica Microsystems, 
Bannockburn, IL, USA) fitted with a 
GFP and Cy5.5 filter and an ORCA 
ER charge-coupled device camera 
(Hamamatsu, Bridgewater, NJ, USA)
 2. eXplore Optix time-domain fluorescence 
imaging system (ART/GE Healthcare, 
Princeton, NJ, USA)
Cell cultures: UM-SCC-1, 
FaDu, CAL 27, and AB12; 
xenograft mice model 
(human head and neck 
squamous cell carcinoma 
cell lines SCC-1, FaDu, 
CAL 27); mice with 
mouse mesothelioma
Can be used to detect tumors 
in vivo
EGFR expression did 
not correlate with the 
fluorescent intensity
IV, 48–72 h 
(optimal)
Alexa-680 labeled 
insulin-like growth 
factor 1 receptor 
(IGF1 R) (AVE-1642-
conjugated Alexa 
680) (46)
575–605 nm 645–850 nm  1. Maestro Imaging System (CRI), in vivo
 2. Olympus Fluoview FV500 laser scanning 
confocal system (Olympus America Inc.)
Xenograft mice model 
(MCF-7 human breast 
cancer cells)
Can detect the downregulation 
of IGF1R after treatment with a 
monoclonal antibody
Further studies 
required to determine 
the amount of 
background 
fluorescence 
produced by IGF1R
1 day (earliest); 
2 days  
(clear imaging)
Folate–fluorescein 
isothiocyanate probe 
(for folate receptor) 
(47)
495 nm 520 nm Intraoperative Multispectral Fluorescence 
Camera System (Institute for Biological and 
Medical Imaging, Technical University)
Humans with ovarian 
cancer
High specificity for labeling 
FR-alpha expressing cells. Real-
time image-guided excision of 
fluorescent tumor deposits of size 
<1 mm was feasible
Four patients 
experienced mild 
discomfort in the 
upper abdominal 
region after injection
Imaging 
completed 2–8 h 
after injection
(Continued)
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Name of probe Reported 
excitation 
wavelength
Reported 
reading 
emission 
wavelength
Used equipment Species tested Advantages Disadvantages Mode of 
administration 
and time 
to imaging 
(unless noted 
otherwise)
BODIPY FL-labeled 
PARP inhibitor 
(Olaparib) (48)
503 nm 515 nm Maestro Imaging System (CRI) Xenograft mice model 
(U87 MG and U251 MG 
human glioblastomas)
High specificity for the DNA repair 
enzyme PARP1 with therapeutic 
effect. Promising new targeted 
antitumor drug, which is already 
in clinical trials. High tumor-
background fluorescent ratio. 
Toxicity profile is known and similar 
to Olaparib
Not mentioned 60–180 min 
(optimal)
Liposomes with 
RGD peptide and 
the neuropeptide 
SP, gadolinium, 
Indium-111, 
Rhodamine-B (49)
554 nm 576 nm Zeiss LSM 510 Microscope (Carl Zeiss 
Meditec AG, Jena, Germany)
Cultured mouse fibroblast 
cells with U87 MG human 
glioblastoma and M21 
human melanoma tumor 
cells (in vitro)
Combination of radioactive, 
fluorescent, and magnetic 
resonance imaging signaling; 
multifunctionality of liposomes as a 
carrier of different probes
Moderate tumor 
uptake
In vitro 
fluorescence 
microscopy was 
completed after 
tumor cells were 
grown in mouse 
fibroblast culture
ZW800-1 zwitterionic 
NIR fluorophore (50, 
51)
750 ± 25 nm; 
773 nm
810 ± 20 nm; 
790 nm
 1. FLARE Imaging System (Beth Israel 
Deaconess Medical Center)
 2. FLARE Imaging System (Beth Israel 
Deaconess Medical Center)
 3. Pearl Small Animal Imaging System  
(LI-COR Biosciences)
Xenograft mice model 
(M21 human melanoma, 
Lewis lung carcinoma, 
HT-29 human colorectal 
adenocarcinoma)
Higher tumor-to-background ratio 
than IRDye800-CW and Cy5.5
Wash-out of dye 
from tumors started 
occurring at 4 h (dye 
still present at 24 h)
4 h, low visibility 
at 4 h, highest 
visibility from 24 
to 72 h
M13-stabilized 
single-walled carbon 
nanotubes  
(SBP-M13-SWNTs) 
(52)
808 nm 950–1400 nm Liquid nitrogen-cooled OMA V 2D InGaAs 
array detector with a 256 × 320 pixel array 
(Princeton Instruments) coupled with SWIR-
25 NIR camera lens (Navitar, Rochester, 
NY, USA)
Xenograft mice model 
(OVCAR8 human ovarian 
epithelial carcinoma)
Stable and showed 10 times more 
selective fluorescent staining of 
ovarian tumor cells than same 
construct without targeting 
peptide. Nanotube fluorescence 
intensity relative to background 
(5.5 ± 1.2) was superior to same 
construct labeled with other NIR 
AlexaFluor750 dye (3.1 ± 0.42) or 
FITC (0.96 ± 0.10)
Study did not assess 
possible penetration 
of the probe into the 
brain
24 h
Fluorescent gold 
nanoparticles 
conjugated with 
diatrizoic acid and 
AS1411 aptamer (53)
400 nm 620 nm (max)  1. Ultra-VIEW RS Confocal System 
(PerkinElmer, Inc., Waltham, MA, USA)
 2. IVIS (PerkinElmer, Inc.)
Xenograft mice 
model (human lung 
adenocarcinoma) 
separate MCF-7 cell 
assay
Specific binding to tumor cells 
due to AS1411 aptamer, which 
targets nucleolin. Allowed X-ray 
visualization due to high electron 
density of gold nanoparticles
Small sample size 
(n = 6)
30 min
(Continued)
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Name of probe Reported 
excitation 
wavelength
Reported 
reading 
emission 
wavelength
Used equipment Species tested Advantages Disadvantages Mode of 
administration 
and time 
to imaging 
(unless noted 
otherwise)
Lymphoma-specific 
fluorescent (Alex488) 
switchable TD05 
aptamer (54)
489 nm 505–535 nm Zeiss 710 laser Scanning Confocal 
Microscope (Carl Zeiss Meditec AG) 
equipped with a 40×/1.2NA water emersion 
objective (ex vivo)
Xenograft rat model 
(U251 human glioma 
and Ramos human CNS 
lymphoma)
Probe could rapidly and specifically 
identify human B cell lymphoma in 
biopsies. System would be useful 
for discriminating non-operative 
CNS B-cell lymphoma from 
malignant glioma rapidly after 
biopsy
Ex vivo only study Total antibody 
staining time 
was 24 h and 
aptamer staining 
time was 1 h 
(ex vivo)
Chlorotoxin (CTX) 
conjugated to ICG 
(BLZ-100) (55)
785 nm Near-infrared 
spectrum
Custom imaging system: 16-mm VIS-NIR 
Compact Fixed Focal Length Lens (Edmund 
Optics, Barrington, NJ, USA) coupled 
785-nm StopLine single-notch filter, NF03–
785E-25 (Semrock, Rochester, NY, USA)
Xenograft mice 
model (LN229 human 
glioblastoma)
High affinity to human gliomas Not mentioned 48 h
5-Carboxyfluorescein 
(FAM)-labeled 
fluorescent probe 
consisting of tLyP-1 
small peptide targeted 
to the neuropilin 
receptors  
(FAM-tLyP-1) (56)
Blue light Not given Kodak In Vivo Imaging System F  
(Kodak, Rochester, NY, USA)
Xenograft mice model 
(U87MG human 
glioblastoma)
Selective uptake. May have 
advantages over CTX-Cy5.5 probe 
due smaller size
Fluorescein labeling 
was less than ideal, 
could be exchanged 
for more intense 
fluorophore
1 h
Activity-based probes
Modified 
hydroxymethyl 
rhodamine green 
(gGlu-HMRG) (57)
488 nm 505–530 nm  1. In-house-made portable fluorescence 
camera for ex vivo tumor specimens
 2. Zeiss LSM510 Microscope (Carl Zeiss 
Meditec AG)
Human breast cancer 
tissue samples; breast 
cancer cell culture
High sensitivity and spatial 
resolution
In breast cancer, 
this method cannot 
distinguish malignant 
and benign regions
5 min
Fast processing: evaluation can 
be done within 5 min after probe 
application
MMPSense 750 FAST 
(MMP-750) (58)
749 nm 775 nm Surgical Navigation System (Institute of 
Automation, Chinese Academy of Sciences, 
Beijing, China) (59)
Mice with 4T1-luc breast 
cancer tumors
Imaging method offered precise 
detection of the orthotopic 
breast tumors and metastases 
intraoperatively in real time
Not mentioned IV, 6 h 
(fluorescent 
signal observed); 
24–36 h (optimal 
fluorescent 
signal)
Caspase-sensitive 
nano-aggregation 
fluorescent probe 
(C-SNAF) (60)
635 ± 25 nm 670–900 nm Maestro Hyperspectral Fluorescent Imaging 
System (CRI)
Xenograft mice model 
(subcutaneous HeLa 
tumors)
Highly feasible for imaging of 
drug-induced tumor apoptosis 
in vivo, signal strengthens as tumor 
cells die
Not mentioned IV, 1 h
(Continued)
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Name of probe Reported 
excitation 
wavelength
Reported 
reading 
emission 
wavelength
Used equipment Species tested Advantages Disadvantages Mode of 
administration 
and time 
to imaging 
(unless noted 
otherwise)
Nanoparticles
Polyacrylamide-
based nanoparticles 
loaded with ICG or 
Coomassie blue dye 
(61)
647 nm 675–725 nm  1. Olympus IX70 confocal microscope 
(Olympus America, Inc.)
 2. Ultra-VIEW Confocal Laser Scanning 
Microscope (PerkinElmer, Inc.)
Cell cultures: 9L rat 
gliosarcoma,  
MDA-MB-435 human 
melanoma, MCF-7 human 
breast cancer
Produced visible color change in 
tumor cell lines
Significant non-
specific binding was 
observed
Imaged after 2 h 
of incubation
Iron oxide magnetic 
NH2-CLIO 
nanoparticles labeled 
with Cy5.5  
(Cy5.5-CLIO) (62)
Not given Not given  1. Custom-built surface reflectance imaging 
system (Siemens Medical Systems, 
Erlangen, Germany), in vivo
 2. Zeiss LSM 5 Pascal (Carl Zeiss Meditec 
AG, Jena, Germany), ex vivo
Rat 9L gliosarcoma tumor 
model
Clear tumor border demarcation Not as accurate as 
target probes for 
in vivo tumor cell 
visualization
IV, 24 h
Co-localization based on MRI 
imaging
Elimination more predictable than 
other nanoprobes
Cyto647 labeled 
anti-EGFR 
antibody-conjugated 
SERS-tagged 
gold nanoparticles 
(antibody-
Panitumumab) (63)
642 nm 
(Olympus); 
785 nm (Raman)
700–775 nm  1. Olympus IX81 inverted fluorescence 
microscope (Olympus America, Inc.)
 2. Hamamatsu Back-Thinned EM-CCD 
camera, 9100-13 (Hamamatsu, 
Bridgewater, NJ, USA)
 3. Spinning Disk Confocal Scanning 
Raman Microscope (Renishaw, Wotton-
under-Edge, UK)
In vitro cell cultures: 
rat gliosarcoma cell 
line 9L; rat C6 glioma; 
human GBM cells U87, 
A172, U251, U373; 
normal fetal human 
astrocytes; primary 
oligodendroglioma tumor 
cells BT2012036; and 
GBM adherent stem cell 
line GLINS1
Selective uptake by tumor 
cells; unlike other fluorescent 
dyes, SERS nanoparticles have 
enhanced photostability
Not mentioned Not applicable
Others
5-ALA that 
metabolically converts 
into fluorescent PpIX
400–410 nm 
violet
620–720 nm 
red
 1. VWCE
 2. Zeiss Pentero Microscope (Carl Zeiss 
Surgical GmbH)
Studies in human (25) and 
in animals (64)
Studies have shown increased 
extent of tumor resection with PpXI 
guided surgery; useful for brain 
tumor biopsy
Disruption of 
BBB necessary 
for fluorophore 
accumulation (can 
decrease/vary 
contrast)
Oral, IV, 2 h (65)
Low fluorescence 
intensity in low-grade 
gliomas
Indocyanine green 
(ICG)
780 nm >795 nm  1. VWCE
 2. Zeiss Pentero Microscope (Carl Zeiss 
Surgical, GmbH)
 3. Zeiss LSM710 (Carl Zeiss Surgical, 
GmbH)
Mice with GL261 mouse 
glioma (66)
Extensively studied; hand-held 
confocal endomicroscope and 
LSM showed ICG selectively 
stained glioma cells in mouse 
model (66)
ICG visualization can 
only be displayed on 
a monitor
IV, 15 min
Human (67) Intraoperative administration at end 
of 5-ALA guided resection may 
show additional tumor tissue (67)
(Continued)
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Name of probe Reported 
excitation 
wavelength
Reported 
reading 
emission 
wavelength
Used equipment Species tested Advantages Disadvantages Mode of 
administration 
and time 
to imaging 
(unless noted 
otherwise)
Fluorescein sodium 
(68)
494 nm 521 nm  1. VWCE
 2. Zeiss Pentero Microscope (Carl Zeiss 
Surgical GmbH)
 3. LSM710 (Carl Zeiss Surgical, GmbH)
Human Convenience for surgeon, 
surrounding tissue has more 
natural color
Rapid 
photobleaching, non-
specific accumulation 
of fluorescein along 
the margins of 
resection. Possible 
extravasation along 
with edema
IV, 5 min (65)
CLR1501 (69) 500 nm 517 nm Nikon A1RSi Confocal Microscope (Nikon, 
Minato, Tokyo, Japan); IVIS Spectrum 
system (PerkinElmer, Inc.)
Xenograft mouse 
model (U251 human 
glioblastoma, 22T, 
22CSC, 33CSC, 
105CSC patient derived 
glioblastoma)
Tumor-to-brain fluorescence ratio 
similar to 5-ALA
Tumor must be 
visualized on 
separate monitor
IV, >4 days
CLR1502 (69) 760 nm 778 nm  1. IVIS Spectrum system (PerkinElmer, Inc.)
 2. Fluobeam 800  
(Fluoptics, Grenoble, France)
 3. Leica OH4 intraoperative microscope 
with FL800 attachment (Leica 
Microsystems, Bannockburn, IL, USA)
Xenograft mouse 
model (U251 human 
glioblastoma, 22T, 
22CSC, 33CSC, 
105CSC patient derived 
glioblastoma)
Tumor-to-brain fluorescence ratio 
superior to 5-ALA
Tumor must be 
visualized on 
separate monitor
IV, >4 days
CH1055 (70) ~750 nm 1055 nm In-house-built NIR spectroscopy instrument 
with Acton SP2300i spectrometer 
(Princeton Instruments, Trenton, NJ, USA) 
and Princeton OMA-V liquid-nitrogen-cooled 
InGaAs linear array detector  
(Princeton Instruments)
Xenograft mice model 
(U87MG human 
glioblastoma)
High tumor-to-background signal 
ratio
Tumor must be 
visualized on 
separate monitor
IV, 6 h (tumor is 
clearly visible); 
72 h (optimal)Possibility for precise image-guided 
tumor removal in the model
90% excreted through the kidneys 
within 24 h
Acridine orange (64) 488 nm 505–700 nm 
(LSM); 
505–585 
(VWCE)
 1. VWCE
 2. Zeiss Pentero Microscope  
(Carl Zeiss Surgical GmbH)
 3. LSM710 (Carl Zeiss GmbH)
Mice with GL261 glioma; 
swine normal brain
Suitable for rapid intraoperative 
ex vivo analysis of glioma tissue
Cannot be used 
in the brain due to 
toxicity profile
Topical 
application, 
immediately
Acriflavine (64) 405 nm (LSM); 
488 (VWCE)
505–585 nm  1. VWCE
 2. Zeiss Pentero Microscope  
(Carl Zeiss Surgical GmbH)
 3. LSM710 (Carl Zeiss GmbH)
Mice with GL261 glioma Suitable for rapid intraoperative 
ex vivo analysis of glioma tissue
Cannot be used 
in the brain due to 
toxicity profile
Topical 
application, 
immediately
Cresyl violet (64) 561 nm (LSM); 
488 nm (VWCE)
620–655 nm 
(LSM); 
505–585 nm 
(VWCE)
 1. VWCE
 2. Zeiss Pentero Microscope  
(Carl Zeiss Surgical GmbH)
 3. LSM710 (Carl Zeiss GmbH)
Mice with GL261 glioma Highlights tumor boundaries ex vivo No current in vivo 
brain application
Topical 
application, 
10 minLow signal-to-noise 
ratio
(Continued)
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violet, and sulforhodamine 101) have been used for pulmonary, 
gastrointestinal, or gynecologic procedures and in ex vivo brain 
biopsies. They have not been used directly in the human brain. 
Fluorescent probes and labels are classified based on the actual 
fluorescent molecule (i.e., intrinsic and extrinsic endogenous 
fluorophores) and excitation/emission profile and can be further 
categorized by their mechanism of action:
 1. Passive fluorescent probes (ICG, fluorescein sodium, and 
other stains);
 2. Metabolic probes (5-ALA, activatable probes); and
 3. Targeted probes.
One of the most important characteristics of the probes is 
their ability to accumulate in tumor tissues in high concentra-
tions. In the case of brain tumors, the blood–brain barrier (BBB) 
influences the delivery of probes that are not lipophilic or have 
a molecular weight more than 400–600  kDa (75). Based on 
their physical properties, photons with longer wavelengths in 
the near-infrared (NIR) spectrum have greater tissue penetra-
tion and thus are advantageous for visualizing obscure residual 
tumor tissue or cells (Figure 1). However, fluorophore phototox-
icity caused by the generation of reactive oxygen species (ROS) 
may be harmful to healthy cells. The principle of phototoxicity 
is also used in combination with fluorescence-guided tumor 
resection and photodynamic therapy (PDT). Most fluorescence 
is associated with the production of some ROS and PDT effects 
(76). The combination of fluorescence-guided resection and 
post-resection cavitary PDT with strong photosensitizers may 
have a synergistic effect and has already shown promising results 
in several clinical trials (77, 78). Nonetheless, this approach and 
the exact methodology regarding the choice of a photosensitizer, 
excitation wavelengths, dosages, and other parameters remain 
to be defined.
In this section, we discuss fluorescent agents that are used or 
could potentially be used for fluorescence-guided resection and 
intraoperative diagnosis of brain tumors.
indocyanine Green
Characteristics
Indocyanine green is a small water-soluble molecule with 
molecular weight of 744.96 Da. ICG is excited at the wavelength 
of about 780 nm, and it emits fluorescence in the 700- to 850-nm 
range, which is not visible to the naked eye. After IV administra-
tion, ICG binds to plasma proteins and is cleared by the liver. 
In brain tumor surgery studies, 5- to 25-mg ICG concentrations 
were used (79, 80), and the observed duration of fluorescence was 
limited, with a peak at about 10 min.
Applications in Brain Tumor Surgery
Indocyanine green video angiography is a widely used method 
for intraoperative assessment of blood flow and vessel patency in 
tissue flap pedicles (81) and for assessment of intestinal perfusion 
near an anastomosis (82). ICG has been extensively studied for 
detection of sentinel lymph nodes in gastrointestinal oncology. 
Lymphatic drainage has been traced after subcutaneous ICG 
administration (83).
FiGURe 1 | A schematic diagram of the light spectrum and corresponding wavelengths. Quantum efficiency of the human eye, standard CCD camera, and 
EMCCD camera are plotted together to show the differences in the covered wavelengths and the sensitivity to light. Light with shorter wavelengths has higher 
energy than light with longer wavelengths. Light wavelengths below 300 nm may burn eyes and skin. UV light of 264 nm is germicidal. Longer wavelengths (infrared) 
have greater tissue penetration properties. EMCCD, electron multiplying charge-coupled device; CCD, charge-coupled device. Used with permission from Barrow 
Neurological Institute, Phoenix, AZ, USA.
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Although we do not discuss ICG angiography for vascular neu-
rosurgery here, assessment of arterial and venous anatomy during 
some tumor resections may be necessary (84). Confirmation of 
the distal circulation with ICG angiography and test occlusion 
may be used when arterial sacrifice is required during tumor 
removal (85).
During a glial tumor resection using the operating microscope, 
ICG injection shows increased blood flow in the tumor tissue and 
pathology-induced alteration in the surrounding brain circula-
tion (86). Hansen initially showed that ICG was able to highlight 
glioma tissue using an in vivo rat model (87), but therapeutically 
adequate doses did not produce sufficient fluorescence and 
required enhanced imaging technologies beyond the standard 
operating microscope (88, 89). Prior administration of bradykinin 
analog reportedly increased ICG extravasation and staining of 
tumor tissue in a glioma model (90) but not in the clinical setting. 
Simultaneous application of ICG during 5-ALA-guided glioma 
resection permitted detection of hypervascularized, angiogenic 
hotspots at the edge of resection potentially increasing the extent 
of resection (67). Although ICG produces an NIR signal with 
deeper penetration, it may not be specific for glial tumor tissue. 
ICG follows proteins leaked from the disrupted BBB and may 
diffuse into surrounding tissues. A unique liposomal formulated 
phospholipid-conjugated ICG has a particular brain-to-tumor 
biodistribution that may allow more accurate imaging guidance 
during surgery than ICG alone (91). Using a hand-held confocal 
endomicroscope, we observed that ICG selectively stained glioma 
cells in vivo (66).
Hemangioblastomas are highly vascularized tumors, and ICG 
fluorescence helps to identify hidden arterial feeders and vessels 
en passage (80, 92, 93). ICG has shown some usefulness in men-
ingioma surgery. In cases of an occluded superior sagittal sinus, 
ICG was helpful in guiding the dural opening, tumor resection, 
and venous management, although multiple ICG injections were 
necessary (94). Additionally, ICG was used to highlight pituitary 
adenoma tissue through a microsurgical approach using the 
operative microscope (95, 96). ICG imaging using an endoscope 
was also recently reported to assist in visualization of tumors that 
infiltrated the sphenoid sinus (97) and to assess blood flow to the 
optic nerves and normal pituitary tissue during transsphenoidal 
surgery (98). ICG has also been used to guide transventricular 
endoscopic biopsies but not all areas of tumor dissemination were 
visible (99). ICG was further applied to visualize the facial nerve 
during temporal bone resection (100). After the facial canal was 
drilled to make it thin, ICG was injected and the fluorescence 
from the nerve blood supply guided further bony dissection to 
the internal acoustic meatus. Thus, the technique allowed visu-
alization and preservation of the facial nerve (100).
One of the drawbacks of ICG visualization is that the image 
can only be displayed on a monitor, and technical refinements are 
needed to increase the comfort and ergonomics of ICG imaging 
instrumentation. Recent advances in this method include an 
overlay of fluorescence video angiography with a white-light field 
transmitted from the conventional operating microscope (101).
5-Aminolevulinic Acid
Characteristics
5-Aminolevulinic acid is a drug that is an intermediate metabo-
lite of the heme synthesis pathway. 5-ALA is converted to pro-
toporphyrin IX (PpIX), which is an endogenous fluorophore. 
PpIX peaks in 6 h after 5-ALA administration (102). Established 
correlation of gadolinium, a marker of BBB breakdown, with 
PpIX concentrations in glioma tissues, suggests (103) that BBB 
disruption is the leading cause of increased 5-ALA accumulation 
in malignant cells. However, increased 5-ALA-induced PpIX 
fluorescence was demonstrated within the areas with preserved 
BBB (104). PpIX has an excitation peak in the violet–blue light 
range (405  nm). Under blue light illumination, normal brain 
tissue reflects the light, whereas tumor tissue with accumulated 
PpIX emits a bright red fluorescence with two peaks, a large peak 
at 635 nm and a small peak at 710 nm.
Interest in 5-ALA application in neuro-oncology has been 
stimulated by promising PDT results with 5-ALA as the pho-
tosensitizer for the treatment of other types of cancers. PDT is 
recognized as a treatment modality mainly for tumors of hollow 
organs such as the stomach, colon, rectum (105), and most 
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successfully, for skin malignancies (106). Its success is mainly 
related to a tumor location close to the surface that allows for 
sufficient depth of penetration by the irradiation.
Applications in Brain Tumor Surgery
For wide-field fluorescence, 5-ALA is usually administered 3 h 
before surgery so that the peak of PpIX production corresponds 
to the intraoperative tumor removal stage. Fluorescence observed 
in glioblastomas is often patchy and varies in intensity. Low-
grade gliomas may not be visualized with wide-field techniques, 
although confocal endomicroscopy may detect 5-ALA in such 
tumors (107). In meningiomas, the observed fluorescence is usu-
ally high in intensity and is homogeneous (108). Tumor-specific 
fluorescence suffers from photobleaching. Natural fading occurs 
about 9  h after administration. 5-ALA-induced fluorescence 
decays to 36% of the peak within 25 min in light filtered to match 
the excitation wavelength of 405 nm; in contrast, with unfiltered 
wide-field illumination, 87 min was required to reach the same 
level of decay (25).
Most studies on glioma surgery with 5-ALA fluorescence for 
guidance have documented increases in tumor resection area 
(109, 110). The results of a phase III study indicated a 1.5-month 
increase in progression-free survival with 5-ALA fluorescence-
guided surgery (111). In patients older than 55 years, regardless of 
tumor location, progression-free survival increased an additional 
6 months. 5-ALA was also successfully used in brain tumor biopsy 
to obtain specimens of higher quality and to make a preliminary 
photodynamic diagnosis in a situation of primary central nervous 
system lymphoma (112).
Several approaches have advanced 5-ALA technology. One 
approach is to calculate the severity of the malignancy based 
on the fluorescence intensity. The emission spectrum must 
be analyzed accurately to calculate the ratio of peak emission 
intensity to the reflected excitation intensity (i.e., fluorescence 
intensity ratio). This ratio can then be used to predict the prolif-
erative activity of the tumor (113). However, investigation of this 
characteristic was done in ex vivo tissue and requires technical 
improvement for intraoperative use. Other potential significant 
advancements for the use of 5-ALA involve the intraoperative 
use of high-magnification imaging optical technologies, such as 
confocal endomicroscopy, which may bring detection of fluores-
cence to the cellular level (107). The results of conventional histo-
pathological methods correlated with confocal endomicroscopic 
imaging during 5-ALA-guided tumor resection (107). However, 
image quality was poor, and in vivo visualization of 5-ALA using 
blue laser confocal endomicroscopy in animal models could 
not confirm the findings (64, 107). Results from various clinical 
trials using intraoperative 5-ALA for brain tumor resection are 
ongoing (114).
5-Aminolevulinic acid, like all fluorophores, has drawbacks. 
Disruption of the BBB is necessary for fluorophore accumulation. 
In some low-grade gliomas, this may decrease or vary contrast 
accumulation. However, recent quantitative measurement studies 
suggest that diagnostic concentrations of PpIX do accumulate in 
low-grade tumors, but the concentration is below the detection 
threshold of current wide-field systems (115). Blood and overly-
ing soft tissues can decrease visible fluorescence and hide the 
residual tumor. 5-ALA consumption and PpIX production may 
be highly variable (116) and depend on the several factors such as 
cell type (117), glucose concentration (118), pH (119), and other 
factors.
Fluorescein
Characteristics
Fluorescein is an orange–red powder with the molecular formula 
C20H12O5 and a molecular weight of 332.31 Da. It is widely used 
in the scientific and medical industries as fluorescein isothiocy-
anate 1 (FITC), Alexa 488 fluorophore, and other variants. In 
medicine, the fluorescein sodium salt is used, but for brevity, we 
refer to it here as fluorescein. Fluorescein as a marker of BBB 
disruption demonstrated perilesional edema in a cortical cold 
lesion model in rats (120). Tumor boundaries observed using 
fluorescein fluorescence correlate well with preoperative gado-
linium contrast-enhanced boundaries (68). However, fluorescein 
has no particular interaction with the tumor cells and may not 
show fluorescence in diffuse, low-density tumor cell infiltrates 
(68, 121, 122).
Application in Brain Tumor Surgery
Although the first clinical use of fluorescein for glioma surgery was 
in 1948 (20), fluorescein use in brain tumor surgery is not currently 
an FDA-approved use. Thus, it is restricted to clinical research 
studies. Its application is reported at several dosages. High doses 
of 15–20 mg/kg have been used for naked eye guidance without 
creating any permanent adverse effects (123). Yellow staining of 
the sclera, skin, and urine after high doses disappeared in approxi-
mately 24 h (124). Lower doses of 5–10 mg/kg for fluorescein-
guided surgery using a special operative microscope module with 
excitation and observation filters were typically safe and effective 
in clinical trials (125), although one case of intraoperative anaphy-
laxis has been reported (126). The timing of fluorescein injection 
also varied across the studies. Some researchers have injected 
fluorescein intravenously after induction of anesthesia (127) at a 
dose of 3–4 mg/kg and waited for 10 min or 1 h, whereas others 
have injected it into a central venous line and waited for 20 min 
before resection (20, 124, 128–130). The half-life of fluorescein 
glucuronide, the main metabolite of fluorescein, is 264 min (131), 
and urinary clearance requires 24–32 h.
Fluorescein accumulates in glioma tissue homogenously and 
may be observed by the naked eye as bright to dark yellow staining 
of the tumor (123). Fluorescein-guided resection using operative 
microscopy without a special fluorescence detection module was 
reported by Shinoda et al. They achieved a gross total resection 
(GTR) in 84% of patients (129). Koc et al. produced GTR in 83% 
versus 55% of controls (132), and Chen et al. achieved an 80% 
GTR rate (123). The study by Koc et al. did not show a differ-
ence in survival (43.9 weeks in the patients given fluorescein and 
41.8  weeks in the control patients) (132) while others did not 
assess survival.
A custom microscope for fluorescein-guided surgery was 
described in 1998 that increased fluorescent enhancement and 
contrast of intravenously injected fluorescein (8 mg/kg) during 
tumor removal (128), although there was diminished fluorescence 
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in gadolinium unenhanced areas (65, 131, 133). The introduc-
tion of special filters to neurosurgical operative microscopes has 
stimulated interest in fluorescein-guided surgery, despite the 
dispute over fluorescein specificity for identifying tumor tissue.
Fluorescein has been used with success to guide removal of 
skull base tumors such as pituitary adenomas, craniopharyn-
giomas, meningiomas, and schwannomas (130). da Silva et  al. 
reported enhancement of a meningioma dural tail by fluorescein 
(134). However, not all brain metastases and not all tumor areas 
were selectively highlighted by fluorescein, and some residual 
non-fluorescent tumor tissue was confirmed on postoperative 
enhanced MRI (135, 136).
Disruption of the BBB is an essential factor determining 
fluorescein extravasation, and several other factors may also 
confound fluorescein-guided glioma surgery. Variations in dose 
and timing of fluorescein administration may result in a variable 
degree of fluorescence in line with other factors such as fluores-
cein extravasation in surgically perturbed tissues, brain swelling, 
and unknown fluorescein distribution (127). Simultaneous 
administration of 5-ALA and fluorescein has shown that fluores-
cein was visible in normal brain and not detected in some areas 
highlighted by PpIX fluorescence (137). Thus, the benefit of fluo-
rescein in guiding resection of malignancies is openly questioned 
and actively discussed. Some researchers warned that fluorescein 
application outside of clinical studies is premature and empha-
sized possible false positive and false negative staining during 
surgery (135). Nonetheless, confocal endomicroscopy with 
fluorescein in patients with brain tumors has revealed promising 
results on par with frozen section pathologic examination as a 
means of optically interrogating tissue (121).
Other Fluorophores
Various new fluorophores and smart-targeted fluorescent probes 
are in different stages of preclinical development. Here, we review 
new fluorescent labels and activity-based and targeted bioengi-
neered fluorescent probes.
Cresyl violet, acridine orange, and acriflavine are fluorescent 
dyes that were investigated for ex vivo use for rapid brain tumor 
tissue diagnosis using confocal endomicroscopy (64, 138). 
Methylene blue was used as a dye to color insulinomas and 
parathyroid glands to a blue hue. When diluted, methylene blue 
also acts as a 700-nm fluorophore and was studied for use in 
parathyroid (139) and breast tumor surgery (140). Methylene blue 
was administered at a dose of 1.0 mg/kg over 5 min and imaged 
with the Mini-Fluorescence-Assisted Resection and Exploration 
(FLARE)™ system. Methylene blue is excreted by the kidneys 
and therefore was investigated as an NIR fluorophore to visualize 
the ureters intraoperatively (141). NIR imaging of meningiomas 
and low- and high-grade gliomas topically stained with 0.05 mg/
ml methylene blue provided good, but not specific, delineation 
of tumor cells (74).
Demeclocycline (excitation/emission peaks at 458/529 nm) is 
a tetracycline antibiotic with phototoxic effects. It has been used 
to demarcate tumor cells when used as an ex vivo stain on various 
human cancer tissues including gliomas (72, 142).
Novel cancer-selective alkylphosphocholine analog fluo-
rophores CLR1501 (green with excitation/emission peaks 
500/517 nm) and CLR1502 (NIR with excitation/emission peaks 
760/778  nm) were reported to have higher tumor-to-normal 
brain fluorescence than 5-ALA (7.23 ± 1.63 and 9.28 ± 1.08 vs. 
4.81  ±  0.92, respectively) in a mouse xenograft glioblastoma 
model (69). Another new fluorophore, a synthetic organic 
molecule CH1055 (970 Da), has a superior depth of penetration 
of almost 4 mm due to the higher emitted wavelength of about 
1050 nm (70). High probe uptake by brain tumors in mice, the 
possibility of conjugation with anti-epidermal growth factor 
receptor (EGFR), and a high tumor-to-background ratio are 
reported. Combining the fluorophore with a radioactive probe 
is another promising surgical method for finding sentinel lymph 
nodes or residual tumor tissue that are deep and do not produce 
visual fluorescence (143), although it may not be useful for 
brain imaging because scintigraphy does not have the precision 
required for brain surgery.
Activity-Based Probes
Several new types of probes referred to as activity-based probes, 
“activatable” probes, fluorescence-quenched probes, or substrate-
based probes were recently designed and investigated in preclini-
cal studies (144–154) and recently reviewed in detail (155). Such 
probes contain a fluorophore that is “quenched” until the probe is 
activated (unquenched) by the given local environment. In caged-
type fluorophores, some modified hydroxymethyl rhodamine 
green (Ac-HMRG; emission peak, 521  nm) probes are highly 
fluorescent when the quenching part of the probe is cleaved by 
its specific enzyme (57). One tumor-labeling strategy is to use 
quenching agents that are reconfigured by tumor-associated 
proteases, which are highly expressed in malignant tumor cells 
aiding invasion. For example, the matrix metalloproteinase-750 
probe is activated by the broad range of matrix metalloproteinase 
family enzymes and facilitates accurate detection and complete 
removal of breast cancer tissue (58). One of the major drawbacks 
of untargeted probes, including activity-based probes, is their 
susceptibility to washout (active or passive removal from the site). 
One probe designed to be unquenched by cathepsin L and further 
covalently bound to protease reduced this limitation (152). Other 
limitations such as topical application of probes with inherent 
waiting time for binding, unknown biodistribution, and pos-
sibly uneven penetration await investigation. The practicality of 
fluorescence-guided surgery dictates that fluorescent tags should 
penetrate or bind to the cancer cells or remain in proximity to 
them for long enough to detect them.
One interesting approach is the design of activity-based probes 
such as caspase-sensitive nano-aggregation fluorescent probe 
(C-SNAF) that microaggregate after cleavage by caspase-3 and 
-7 by intramolecular cyclization (60). Another exciting approach 
is the complex activity-based probe. The construct is synthesized 
by combining a cell-penetrating peptide that may be activated 
and a nanoparticle labeled with gadolinium and Cy5 fluorophore. 
This complex probe is taken up by the tumor cells after matrix 
metalloproteinases 2 and 9 cleave the peptide and activate its 
cell-penetrating domain. In a murine model, gadolinium allowed 
in  vivo visualization of the tumor using MRI and Cy5 allowed 
fluorescence detection (156). The advantages of such probes are 
the ability to carry several labels for various types of detection, 
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high contrast to the background, and applicability to a wide range 
of tumors. However, this model was not tested for application in 
brain tumors.
Molecular Targeted Probes
Molecular targeted probes are also known as affinity-based 
probes. Targeting molecules with colored and fluorescent dyes 
has revolutionized microscopy. Application of this method of 
visual guidance for tumor resection is under investigation in cell 
cultures and animals by several research groups (149–154, 157, 
158). Many known tumor targets such as EGFR, HER2, CD105, 
VEGFR, and folate receptors have been tested for fluorescence 
visualization of tumors. Additionally, targeting and highlighting 
of normal peripheral nerves have been investigated to prevent 
nerve injury during surgery (159).
Molecular targeted probes may be classified based on the fluo-
rophore, targeted molecule, and other components. The majority 
of the targeting molecules fall into three categories:
 1. Antibodies;
 2. Recombinant antibody mimicking binders:
 a. Affibodies: small (6.5-kDa) single domain engineered pro-
teins that bind target proteins, imitating antibodies (160).
 b. Nanobodies: a single variable domain of an antibody, 
which is capable of specific binding (161).
 3. Aptamers: short single strands of nucleic acids, which are 
capable of specific binding (162, 163).
The rapid growth of targeted molecular probes has occurred 
because of the development of new fluorophores that may be 
conjugated to a variety of specific targeting molecules. Numerous 
possible combinations, including the possibility of adding a sec-
ond (or more) label, significantly increase this potential. Many 
fluorophores have become commercially available and are being 
investigated in numerous preclinical and several clinical trials. 
Two clinical trials of IRD 800CW-labeled probes for visualization 
of breast cancer and familial adenomatous polyposis have been 
completed (164, 165), and other trials are recruiting patients 
(166–172) for the use of the Cy 5.5-labeled probe (173). However, 
none of these trials involve brain tumors. A promising fluorescent 
label, zwitterionic NIR fluorophore, ZW800-1, was recently 
described (50). ZW800-1 has great promise as it shows a higher 
tumor-to-background ratio than IRDye800-CW and Cy5.5 
in vitro and in vivo (17.2 vs. 5.1 and 2.7, respectively) (50, 51).
The major drawbacks of targeted molecular probes are uneven 
passive distribution and non-specific binding. Dual-labeled probes 
were designed to address this limitation (174). This approach 
uses targeted probes that bind, and untargeted probes that do not 
bind, to the target. Differentiation in the fluorescence intensity 
allows a quantitative assessment of the binding potential of the 
probe (175, 176). Another drawback is that tumor regions with 
an undisrupted BBB can decrease the accumulation of the large 
probes. Sexton et al. addressed this problem by designing a small 
targeted fluorescent affibody peptide (about 7 kDa vs. 150 kDa for 
a full antibody) and demonstrated in a mouse xenograft GBM 
model almost two times increased fluorescence at the tumor edge 
compared to the full anti-EGFR antibody probe (42). Gong et al. 
showed that both anti-EGFR-specific affibody and the therapeu-
tic antibody panitumumab labeled with IRDye 800CW could be 
used as imaging agents for both wild-type EGFR and EGFRvIII 
glioblastoma cells in cell culture studies (177).
In a 2014 report, Ghosh et  al. described a novel targeted 
probe construct containing a single-walled carbon nanotube as 
a fluorescent tag (52). It consists of an M13 bacteriophage as a 
scaffold, a targeting protein, and the fluorescent nanotube. The 
single-walled carbon nanotubes have emission within the NIR 
range (950–1400  nm), resulting in less optical scattering and 
deeper tissue penetration. This setup is also less susceptible to 
photobleaching or quenching effects. The construct was stable 
and showed 10 times more selective fluorescent staining of ovar-
ian tumor cells than the same construct without the targeting 
peptide. The nanotube fluorescence intensity ratio relative to 
the background (5.5 ± 1.2) was superior to the same construct 
labeled with other NIR AlexaFluor750 dye (3.1 ± 0.42) or FITC 
(0.96 ±  0.10). However, this study did not assess the possible 
penetration of the probe into the brain (52).
A targeted probe consisting of fluorescent gold nanoparticles 
conjugated with diatrizoic acid and AS1411 aptamer (53) has 
an absorption band of 300–400 nm and orange–red emission 
(maximum 620 nm), which can be observed by the naked eye. 
This probe showed specific binding to tumor cells due to the 
AS1411 aptamer, which targets nucleolin. The probe allowed 
X-ray visualization due to the high electron density of the 
gold nanoparticles. A novel lymphoma-specific fluorescent 
(Alex488) switchable TD05 aptamer in a human brain tumor 
xenograft model has been described (54). This probe rapidly 
and precisely identified human B cell lymphoma in biopsies. 
Such a system would be useful for rapidly discriminating non-
operative CNS B-cell lymphoma from malignant glioma based 
on the biopsy.
Another agent, BLZ-100, a tumor ligand chlorotoxin conju-
gated to ICG, was shown to have high affinity to human gliomas 
in mice (55). Chlorotoxin was extensively studied in preclinical 
in vivo studies as a conjugate with Cy 5.5 (178) and IRDye 800CW 
(179). Chlorotoxin is a new drug that binds to chloride  channel–
MMP-2 membrane complexes. It reduced the invasiveness of 
glioma cells (180), inhibited glioma cell growth and metastasis, 
and accelerated tumor apoptosis (181). The advantage of the 
probe is its small size and ability to penetrate the BBB.
Another 5-carboxyfluorescein-labeled fluorescent probe 
consisting of tLyP-1 small peptide targeting neuropilin receptors 
was recently described. Neuropilin receptors are co-receptors 
for vascular endothelial growth factor and play a role in tumor-
mediated angiogenesis. They are overexpressed in most gliomas. 
The probe has selective uptake and may have advantages over the 
CTX-Cy5.5 probe due to its small size. However, the fluorescein 
labeling was less than ideal and could be exchanged for a more 
intense fluorophore for use in intraoperative imaging (56).
IRDye800CW-labeled anti-EGFR nanobody 7D12 was 
compared to the full antibody cetuximab and showed better 
penetration and distribution of the nanobody probe in  vivo in 
a preclinical study (40). Another study of the same nanobody 
for orthotopic tongue tumors showed significantly higher tumor 
to background fluorescence (2.00 ± 0.34 in the FLARE imaging 
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Schematic view of the concept of PpiX-guided tumor visualization using a wide-field operative microscope with appropriate filters. Wavelength scales 
are in the same position in the figure. The illumination device emits light in the wavelength band less than 470 nm. The excitation filter then transmits light with the 
peak of about 405 nm. PpIX, which is accumulated in the tumor cells, absorbs photons in the spectrum band around 405 nm and then emits photons of lower 
energy at a wavelength of about 630 nm. The blue light from the illumination device and the emitted red fluorescence band are observed through the operative 
microscope optics equipped with an emission (observation) filter. This filter has a cut-off transmittance at about 450 nm and cut-on transmittance at about 570 nm. 
The two bands of light observed fall into the visible spectrum (with the naked eye) and are perceived as a violet–blue background and “pink-to-red” fluorescence. 
The light in between those two bands is blocked; therefore green, yellow, and orange colors are not visible. PpIX, protoporphyrin IX. Used with permission from 
Barrow Neurological Institute, Phoenix, AZ, USA.
15
Belykh et al. Fluorescence-Guided Precision Neuro-Oncology
Frontiers in Surgery | www.frontiersin.org October 2016 | Volume 3 | Article 55
system) than in the group with the same non-targeted fluorescent 
probe (41).
Polyacrylamide nanoparticles have been coated with the F3 
protein that binds to nucleolin and loaded with methylene blue, 
Coomassie blue, or ICG. F3-coated constructs increased the color 
change in glioma cells in vitro (61). Magnetic NH2-cross-linked 
iron oxide nanoparticles labeled with Cy5.5 (32 nm in diameter) 
produced clear tumor border demarcation and co-localization on 
MRI imaging in a rat gliosarcoma model (62). As a non-targeted 
construct, it produced demarcation mainly due to BBB disruption 
and was designed as a magneto-optical probe. Additionally, iron 
oxide particles are eliminated by reticuloendothelial cell endocy-
tosis (182), suggesting that their elimination is more predictable 
than that of other nanoprobes. However, this magnetic nanopar-
ticle design is less attractive than that of targeted probes, which 
aim to increase the accuracy of tumor cell visualization in vivo.
Summarizing fluorophore use in neurosurgery, 5-ALA-guided 
brain tumor surgery may improve the gross tumor resection rate 
and is approved in Europe but is available only in clinical tri-
als in the US. Fluorescein-guided resection has emerged as an 
alternative due to its safety profile, although fluorescein is not 
tumor cell-specific. ICG shows promise for vascular tumors, 
such as hemangioblastomas, but may also have the potential to 
define malignant gliomas. Many new targeted and activatable 
fluorescent probes are awaiting full assessment to be used in clini-
cal studies. Although molecular targeting probes are attractive 
and technologically advanced, their benefit and cost compared to 
already existing 5-ALA and fluorescein for fluorescence-guided 
resection are yet to be proven. Assessing the advantages of the 
many probes being designed is a difficult and time-consuming 
task considering the emerging improved, quantitative fluorescent 
detection methods. Combining the probes with molecules for 
secondary goals such as chemotherapy, photosensitization, and 
others may be advantageous.
iNSTRUMeNTATiON FOR 
FLUOReSCeNCe-GUiDeD ReSeCTiON
Several different technologies are applied in fluorescence-guided 
resection of brain tumors. These technologies are classified into 
several categories (183–187):
 1. Wide-field fluorescence imaging:
 a. Commercial operative microscopes with built-in fluore-
scence channels;
 b. Custom modified surgical microscopes;
 c. Surgical endoscopes equipped with fluorescence modules;
 d. Non-microscope fluorescent excitation systems with emis-
sion detecting devices.
 2. Quantitative fluorescence systems:
 a. Spectroscopic tools for imaging one region at a time;
 b. Laboratory grade stand-alone systems;
 c. Combination systems that integrate fluorescence with spa-
tial imaging.
 3. Intraoperative high-resolution endomicroscopy.
wide-Field Fluorescence imaging
Wide-field fluorescence imaging refers to non-microscopic, 
endoscopic, or microsurgery in which full fields of view are seen 
continuously through the eyepieces or on the screen during 
image acquisition at a rapid frame rate with a digital detector 
array (CMOS or CCD cameras) (184). Several instrument solu-
tions exist for wild-field fluorescence imaging. By definition, such 
systems have a magnification of 5× to 40× and resolution of less 
than cellular level. Fluorescence-guided surgery is undergoing 
revitalization as advancements in optics are allowing improved 
visual perception of fluorescence. Numerous neurosurgical 
studies highlight the benefits of wide-field fluorescence-guided 
glial tumor resection, mainly to increase the GTR rate and 
progression-free survival (2, 111, 188). Some studies even showed 
increased overall survival (189).
Instruments
The use of custom operative microscopes with modules to meas-
ure fluorescein (128) and PpIX (190) fluorescence was reported 
in 1998. There are three fluorescence detection modules, for use 
on commercially available operative microscopes for 5-ALA- 
(Figure 2), ICG- (Figure 3), and fluorescein-guided (Figure 4) 
tumor resection in the brain. The modules consist of three com-
ponents: (1) a set of optical filters for selective wavelength separa-
tion, (2) a broad-spectrum illumination device, and (3) optional 
CCD cameras for detection of visible and invisible (NIR) light 
(Figure  3). New optical filters for selection of bandpass width 
and blocking intensity are now available due to progress in optical 
engineering. A combination of these new filters permits the best 
possible fluorescence intensity and contrast to the background 
ratio. One example is the new Yellow 560 Module for the Zeiss 
operative microscope that reintroduced fluorescein in brain 
tumor surgery. A set of filters facilitates excitation of the fluores-
cein with the maximum intensity while preserving illumination 
of the background with another visible spectral band of lower 
intensity (Figure  4). The resulting bright yellow fluorescence 
of tumors is observed and contrasted with the natural colored 
background (191).
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Schematic view of the concept of iCG fluorescence visualization using a wide-field surgical microscope with appropriate filters. Wavelength scales 
are in the same position in the figure. The illumination device (xenon lamp) emits light in a wide range of wavelengths. The excitation filter cuts off the light longer 
than about 750 nm. ICG present in the tissue (vessels) absorbs photons in the available spectrum band below 750 nm and then emits photons in a NIR 
spectrum around 820 nm, invisible to the naked eye. The emission filter then transmits this NIR light to the CCD camera and blocks the light with other 
wavelengths. The CCD camera records the images during the desired period. After image processing, the resultant surgical picture is displayed on the monitor 
of the neurosurgical microscope in the grayscale as a short movie fragment. ICG, indocyanine green. Used with permission from Barrow Neurological Institute, 
Phoenix, AZ, USA.
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Fluorophores that emit in the NIR spectrum require CCD 
cameras or other detection technologies. An ICG (NIR) module 
does not require an operative microscope per  se because the 
resultant fluorescence is not perceived by the eye and is observed 
on an ancillary screen. The fact that NIR probes are in abundance 
and are either commercially available or awaiting approval by the 
FDA (ICG, Cy 5.5, IRDye800-CW, and BLZ-100) has stimulated 
the field of computer engineering to develop wide-field systems 
that overlay an NIR signal on the surgical field of view. Such an 
overlay is desirable in real time and with measurable specificity. 
Non-microscopic, mobile, wide-field video imaging systems for 
open, laparoscopic, thoracoscopic, and robotic surgery are in 
development and clinical trials (192, 193).
Work in intraoperative NIR imaging technologies in neuro-
surgery shows potential for advantageous applications. A novel 
proof-of-concept NIR imaging system consists of a narrow-band 
laser at 785  nm, a notch filter, and a standard 2-CCD camera 
for wide-field visualization. This system has been tested with an 
ICG-conjugated targeted BLZ-100 probe in a murine brain tumor 
model (55).
A new endoscopic technology, scanning fiber endoscopy 
(194), also holds great promise due to its ultrathin probe and 
increased resolution. A color image is acquired by combining 
red, blue, and green laser lights through a spiral actuated optical 
fiber. Laser induced fluorescent imaging of 5-ALA-induced PpIX 
fluorescence on tumor cell phantoms (195) and a murine tumor 
model (work in progress) allowed detection of the fluorescence 
with greater sensitivity than through the operative microscope. 
We found this optical imaging technology very convenient for 
potential intraoperative use due to its small size with a field of 
view of 2–30 mm and high spatial resolution of up to 15 μm.
A concept for a low-cost fluorescein detection system for 
glioma surgery (196) consists of a xenon light source, fiber optic 
light cable, a set of glass interference filters (neutral, 490  nm, 
465 nm), and yellow photographic filters for oculars or UV yellow 
glasses. In clinical trials, the system showed great potential due 
to its low cost, especially beneficial for low-income countries, 
although limitations of the custom hardware and fluorescein use-
fulness in glioma surgery itself still require confirmation (127).
Limitations of wide-field visualization technologies in 
fluorescein-guided surgery are similar to those of 5-ALA stud-
ies. Wide-field, fluorescence-guided surgery limitations include 
(184) ambiguity at the margins where fluorescence intensity 
decays and difficulty of visualization on the sides of a resection 
cavity and shaded areas in the surgical wound. Further limita-
tions include fluorescence absorbance by blood and tissue layers 
(197), insufficient fluorescence intensity in >95% of low-grade 
gliomas (107, 198, 199), and lack of quantitative assessment of 
fluorescence intensity. In PpIX fluorescence visualization, PpIX 
is quantitatively related at the microscopic level to increasing 
malignancy in both low- and high-grade gliomas (117). Such 
works emphasize the limitations of fluorescence detection by 
the current wide-field technologies at low concentrations of the 
fluorophore or when few cells are labeled. New approaches that 
increase the sensitivity of visualization systems include the use 
of a quantitative spectrophotometer, an additional camera for 
quantitative image processing (200), and new endoscopic and 
confocal endomicroscopy probes.
intraoperative Quantification of 
Fluorescence
Absorption, scatter, anisotropy, and autofluorescence of the tumor 
and background tissue play important roles in the detection of 
the fluorophore signal, especially at low signal levels. Thus cor-
rections for the optical properties of the tissues provide qualita-
tive information about the fluorescence intensity in the area of 
interest (193). For this reason, researchers have studied the utility 
of spectrophotometric quantification of PpIX emission spectra. 
Visual light spectroscopy for the calculation of the background 
fluorescence intensity ratio has been investigated in postoperative 
astrocytoma samples (113). The fluorescence intensity correlated 
with the MIB-1 proliferation index, a prognostic indicator for 
tumor progression.
A spectrally resolved quantitative fluorescence imaging sys-
tem with submillimeter spatial resolution (214–125 μm) has been 
integrated with a conventional operative microscope (200). This 
system provides a colored digital overlay of the quantitative fluo-
rescence intensity map over the surgical field of view. A pilot study 
of human glioblastoma surgery showed that the system showed a 
signal from histologically confirmed residual tumor tissue when 
the standard wide-field BLUE400 filter image was negative (200). 
Quantitative PpIX detection elevated the diagnostic sensitivity of 
low-grade gliomas (67% in 12 cases) to the level of qualitative wide-
field detection of high-grade gliomas (115). Improved sensitivity 
with PpIX fluorescence was confirmed using an ex vivo animal 
tumor model with a similar system that included a CCD camera 
attached to the operative microscope (201). Quantification using 
the intraoperative contact optical probe demonstrated increased 
accuracy in detecting neoplastic meningioma tissue with a 90% 
diagnostic accuracy for differentiating tumor from the normal 
dura in 10 grade 1 meningiomas (108).
intraoperative Confocal endomicroscopy
The rationale for high-resolution intraoperative imaging is 
the inherent limitations of wide-field fluorescence microscopy 
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Schematic view of the concept of fluorescein-guided tumor visualization using a wide-field operative microscope with appropriate filters (https://
www.google.ch/patents/US8730601). Wavelength scales are in the same position in the figure. The illumination device (xenon lamp) emits light in a broad range 
of wavelengths. The excitation filter then transmits the light as narrow bands at about 450–520 nm and about 600–750 nm. The first (blue–green) transmittance 
band is significantly more intense (see log scale on the side of the filters in the figure) than the second (red) band of light. Fluorescein, which is accumulated in the 
tumor tissue, absorbs photons in the spectrum band around 485 nm (high-intensity band) and then emits photons with a wavelength around 514 nm (yellow) with a 
lower energy (new low-intensity yellow band). Blue–green and red bands of light from the illumination device, as well as the new yellow (around 514 nm) 
fluorescence band, are observed through the operative microscope optics equipped with an emission (observation) filter. This emission filter has a transmittance in 
two bands: first in the range of 475–515 nm with significantly lower transmittance (see log scale in the figure) and the second in the range of 530–700 nm with the 
maximum transmittance. The three bands of light, the blue–green emission band, red band, and emitted yellow band, all fall into the naked-eye-visible spectrum for 
observation. The transmittance of all filters together results in the uniform intensity of all bands, with a higher possible intensity of emitted yellow light. A portion of 
the spectrum between the bands could be blocked by the filters, but the remaining three primary color bands allow the surgeon to see the intraoperative picture 
with almost the full spectrum of colors. Used with permission from Barrow Neurological Institute, Phoenix, AZ, USA.
FiGURe 5 | intraoperative use of a hand-held confocal 
endomicroscopy probe co-registered with a StealthStation 
neuronavigation system during brain tumor surgery. Used with 
permission from Barrow Neurological Institute, Phoenix, AZ, USA.
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and the desire for precise tissue visualization at the cellular 
level. Fiber optic confocal microscopy was invented in 1988 
(202), commercialized in 1994, and the first results of use in 
neurosurgery were published in 2010 (122). Such systems con-
sist of a miniature handheld probe and movable workstation 
with an LCD screen (Figure 5). Excitation and emission light 
is transmitted through a single optic fiber. The system provides 
non-invasive real-time imaging through optical sectioning at a 
known depth. Most importantly, it appears to provide real-time 
images for histopathological analysis without the laborious 
process of tissue preparation, although this development is still 
being validated (Figure 6) (203). Two commercially available 
systems include the Optiscan FIVE 11 and Cellvizio.2 Both 
systems  have been reviewed for neurosurgical applications 
(186). The Optiscan has a 475 μm × 475 μm field of view with 
a focal plane to a depth of 250 μm, and the Cellvizio has nine 
objectives covering fields of view ranging from 300 to 600 μm 
and 15 to 70 μm optical sectioning depth. The Cellvizio and 
Optiscan currently use a 488-nm excitation light, and the 
Cellvizio also has a 660-nm single-band excitation light. The 
1 www.optiscan.com 
2 www.maunakeatech.com 
first feasibility study of intraoperative confocal endomicros-
copy was reported for a variety of brain tumor pathologies in 
33 patients with intravenous fluorescein injection for tumor 
visualization (204). Intraoperative imaging permitted the 
neuropathologist to make a diagnosis, but this diagnosis was 
not compared with standard histological staining for accuracy 
(205). Another study using confocal endomicroscopy enabled 
the correct diagnoses based on intraoperative images (fluores-
cein) in 26/28 of cases (206). A clinical series of 74 patients 
who underwent intraoperative confocal endomicroscopy 
showed diagnostic specificity and sensitivity for gliomas of 
94 and 91%, respectively, compared to the interpretation of 
frozen section and permanent histologic diagnoses (121). 
Ongoing studies of this technology aim to improve these 
indices.
Confocal endomicroscopy may also be employed as a rapid 
diagnostic tool for biopsy specimens in ex vivo tissue analysis 
within the operating room. The utility of fluorescein, 5-ALA, 
acridine orange (stains DNA/RNA/lysosome), acriflavine (topi-
cal application, stains membrane/DNA), cresyl violet (topical 
application, stains ER/cytoplasm), and sulforhodamine 101 
(topical application, stains glial cell cytoplasm) for visualization 
of tumor cells was demonstrated with the Optiscan 5.1 system 
(64, 122).
Although 5-ALA visualization was not optimal due to the 
limitation of the probe excitation profile, the other fluorescent 
stains clearly showed the histological features of the tumor cells 
and margins in a murine brain tumor model. Normal morphol-
ogy in various brain regions was also clearly discernible in a 
large animal model (pig) using confocal endomicroscopy with 
topical acridine orange. Selective detection of ICG in a murine 
glioblastoma model was also shown using a clinical-grade, NIR 
confocal endomicroscopic system (64).
The initial experience with the Cellvizio confocal endomi-
croscope for immediate ex vivo imaging of human intracranial 
tumors after fluorescein-guided resection combined with topical 
acriflavine staining shows practical potential (138). Although 
rapid histopathological diagnoses were possible for a wide variety 
of brain neoplasms, this application is pending comparison with 
standard histological staining in validation assessments. Clinical 
trials of the Cellvizio system for brain tumors are underway in 
Europe to assess the neuropathological diagnostic agreement 
and completeness of tumor removal (207–209). Furthermore, 
the confocal endomicroscope was successfully used to visualize 
FiGURe 6 | intraoperative images of meningioma and glioma after intravenous fluorescein sodium injection taken with the confocal endomicroscopy 
probe and shown with corresponding histopathological pictures. Used with permission from Barrow Neurological Institute, Phoenix, AZ, USA.
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targeted probes consisting of two tyrosinase-related protein 
antibodies labeled with Alexa Fluor 488 fluorescent dye (210). 
In a murine brain tumor model, these probes correctly identified 
tumor cells with high specificity, confirming in principle that the 
targeted probes could be used along with the confocal endomi-
croscope to increase the extent of resection in a variety of brain 
tumors (211).
The inherent limitations of the intraoperative confocal 
endomicroscope are a narrow field of view, the image appear-
ing on a separate display, and the necessity of non-standard 
image analysis and interpretation, along with limited resolu-
tion, laser excitation spectrum, and corresponding detection 
power. Several computer image processing methods have been 
proposed to improve the diagnostic value of these small-field-
of-view systems. For example, an image stitching technique 
has been applied to create panoramic wide-field images 
(212–214). Multiple histogram operations provide image 
contrast enhancement (215). Image quality and its diagnostic 
value, as well as the surgeon’s knowledge of histopathology, are 
important factors in the practical application of intraoperative 
confocal endomicroscopy because the resultant images differ 
from the stained histopathological slides and require additional 
training for interpretation. Additionally, the probe should be 
in a stable position during image acquisition, although the 
surgeon may acquire good images in the free-hand mode with 
practice.
Approval of targeted fluorescent probes for clinical use will 
likely stimulate the refinement of confocal endomicroscopy and 
its broad clinical use in neurosurgery and tumor pathology. 
These two technologies are complimentary and allow tailored, 
tumor-specific resections for personalized patient treatment and, 
certainly, precision tumor surgery. The ability to interrogate the 
tumor border optically is of significant advantage in the acquisi-
tion of selective biopsies of higher diagnostic yield. Such a situa-
tion could improve the neurosurgery–neuropathology workflow 
for increased efficiency.
FUTURe DiReCTiONS
Several studies in optics, bioengineering, biotechnology, experi-
mental oncology, and biochemistry have advanced the field 
of fluorescence-guided surgery in the preclinical arena (216). 
Because many fluorophores emit light in the NIR band, outside of 
the visible spectrum, improvements in overlay imaging technol-
ogy are expected. Pharmacological and toxicological restrictions 
stimulate the application of “microdoses” of a fluorophore, 
which, in turn, may allow for approval for clinical use. Moreover, 
the fluorophores in use still require more sensitive detectors. The 
need for these features drives the focus of future system devel-
opments in fluorescence-guided surgical imaging and overlay 
techniques (216).
Pulsed-light imaging is a technology that exploits pulsed 
excitation light and time-gated detection. It allows fluorescence 
imaging under normal operating room light conditions with high 
detection sensitivity (217). This technology is more sensitive to 
lower concentrations of PpIX than surgical microscopy (217).
A novel type of fluorophore, quantum dots, appears to be a 
relevant nanotechnology for fluorescence. The quantum dot is a 
5- to 20-nm nanocrystal made from a semiconductor material 
that acts like a traditional fluorophore but works by a different 
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mechanism. The emitted wavelength of the quantum dot depends 
on the size of the crystal. Fluorescent probes with the desired 
emission band may be designed. The main advantages of the 
quantum dot are much longer excitation life leading to photosta-
bility. The color of the emitted light may be tuned to the size of the 
probe. However, the safety of quantum dots is significant because 
larger quantum dots may not be well cleared, and the long-term 
effects of accumulation are unknown (218, 219). Quantum dots 
conjugated with transferrin have been used as a fluorescent probe 
to target transferrin receptors in glioblastoma cells (220).
Another important parameter of future fluorophore probes is 
the size of the molecule, in which small targeted molecules, even 
with lower affinity, show better delineation of tumor boundaries 
most likely due to crossing the BBB more easily (42). In another 
approach, the BBB is reversely disrupted to allow more intense 
binding to the tumor tissue. Several methods to bypass the BBB 
were developed (221, 222) to enhance targeted fluorescent probe 
binding to brain tumor tissue and were tested in animals (63).
Some other emerging technologies may help in differentiat-
ing normal tissue from brain tumor tissue. For example, optical 
coherence tomography does not require any targeting agent. The 
technology utilizes differences in the optical signatures of the 
tissues to differentiate brain tumor from normal tissue, as shown 
in an animal study (223).
Intraoperative fluorescence imaging is capable of maximizing 
tumor tissue resection, providing rapid histopathological diagno-
ses based on innovative fluorophore probes and tools for intraop-
erative visualization. What is clear is that we sit on the threshold 
of technology that will enable neurosurgeons to see tumor cells 
in groups or individually in real time, which will allow tailoring 
or personalization of neurosurgery in terms of tumor resection. 
The term “theranostics” was coined to define ongoing efforts to 
develop precise, specific, individualized diagnostics and thera-
peutics for various diseases. For neurosurgery, we are adapting 
true precision modalities or biomarker techniques into diagnosis, 
including the imaging techniques described here, and this facili-
tates precise approaches to surgery. Cell-specific visualization will 
make possible the optimal surgical treatment of invading tumors 
such as gliomas that are composed of heterogeneous tissue with 
various genetic and metabolic characteristics. Therefore, the 
previously impossible may become routinely possible. If invad-
ing tumor cells are discovered in eloquent cortex, which is not 
normally resected, the neurosurgeon might be able to proceed 
on a cell-by-cell basis, targeting only tumor cells. Improved imag-
ing technologies will bring about novel techniques to target or 
remove tissue or even individual cells. The advantages of such 
techniques are better surgical outcomes as nearly “cell-by-cell” or 
precision surgery becomes possible. Such surgical advancements 
will undoubtedly come with additional responsibilities, decisions, 
and challenges to be faced by both the neurosurgeon and patient.
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